Skip to content
Dendreon
  • News
  • Contact Us
  • About
  • Science and Services
    • Cellular Therapy Manufacturing
    • Provenge Immunotherapy
  • Publications
  • Careers
News Real-World Evidence Shows Adding PROVENGE® (Sipuleucel-T) To Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival By 14.5 Months
October 14, 2020

Real-World Evidence Shows Adding PROVENGE® (Sipuleucel-T) To Advanced Prostate Cancer Treatment Regimen Prolonged Median Survival By 14.5 Months

  • News Type: Press Releases
Read More
LinkedInShareTweet
Dendreon
© Dendreon Pharmaceuticals LLC. All Rights Reserved. 2023.
  • Privacy Policy
  • Legal Notice
  • Site Map
  • Linkedin
  • Facebook
  • Twitter